Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma

Marginal zone lymphoma (MZL) is challenging to treat, with many patients relapsing following initial treatment. We report the long-term efficacy and safety of copanlisib, a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, in the subset of 23 patients with relapsed/refractory MZL treated in th...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Panayiotidis, Panayiotis, Follows, George A., Mollica, Luigina, Nagler, Arnon, Özcan, Muhit, Santoro, Armando, Stevens, Don, Trevarthen, David, Hiemeyer, Florian, Garcia-Vargas, Jose, Childs, Barrett H., Zinzani, Pier Luigi, Dreyling, Martin
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2021
Témata:
Lymphoid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7876879/
https://ncbi.nlm.nih.gov/pubmed/33560394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002910
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky